Royal Biologics

Name

Royal Biologics

Legal name

Royal Biologics Inc.

Website

https://royalbiologics.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Orthobiologics and Wound Care Biologics

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)

akta.pro secondary industries

Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH), Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE), Cell Therapy Developers (Autologous) (HLAAABAA)

Keywords

• Orthobiologic medical devices
• Autologous biologic therapies
• Bone graft substitutes
• Wound care biologics
• Platelet-rich fibrin matrix

Headquarters

HQ city

Hackensack

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Marketing or Sales, Personnel, Operations

Revenue model

1. Biologic Medical Devices and Implants: Royal Biologics generates revenue through the sale of biologic medical devices, bone grafts, wound care products, and cellular therapy systems. Products are sold to healthcare providers, hospitals, and through distributor networks for use in surgical procedures.
2. Wound Care Biologics: Sale of Fibrinet PRF Wound Matrix and related wound care products with Medicare/insurance reimbursement codes (G0465, G0460) enabling healthcare facilities to bill for treatments.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Royal Biologics develops, manufactures, and distributes a portfolio of autologous advanced biologics, cellular bone grafts, traditional bone grafts, advanced synthetic bone graft substitutes, and wound care biologic products. Its devices include systems such as Fibrinet (platelet-rich fibrin matrix), Maxx-Cell (bone marrow aspiration), MAXX BMC/PRP (concentration systems), Osteo-Spin (live cellular graft platform), Magnus (DMSO-free cellular allograft), and Bio-Reign (bioactive/synthetic bone grafts). Products are sold to orthopedic and wound care specialists, hospitals, and surgical centers in the U.S. through a distributor network and direct field sales.

Product overview

Royal Biologics is a premier orthobiologics and life science company offering a comprehensive portfolio of autologous advanced biologics, cellular bone grafts, traditional bone grafts, advanced synthetics, and wound care solutions. The Autologous Advanced Biologics line includes Fibrinet® (PRFM system), Fibrinet® PRF Wound Matrix (FDA-cleared wound care), Maxx-Cell® (bone marrow aspiration), MAXX BMC® (bone marrow concentration), MAXX PRP® (platelet-rich plasma), Osteo-Spin® (cellular graft technology), and Advanced Cell™ (convenience kit combining multiple technologies). The Cellular Bone Graft portfolio features Magnus® (DMSO-free allograft). Traditional Bone Grafts include Maxx Fuse (DBM products). Advanced Synthetics encompass Bio-Reign® 3D, Bio-Reign®, and Bio-Reign Luxe™ (synthetic bone graft substitutes). Wound Care products include Cold Plasma Therapy and Collagen Type Zero (jellyfish-derived collagen from partnership with Jellagen). The company also distributes Myriad Matrix™ Restore via exclusive agreement with Aroa Biosurgery.

Differentiator

Problem solved

Functional benefit

Brands

• Royal Wound-X: Wound care division of Royal Biologics that prioritizes patients by providing innovative wound care and biologic solutions that enhance healing and improve quality of life.
• Fibrinet
• Maxx-Cell
• Bio-Reign
• Magnus

Products and services

• Fibrinet Point-of-care platelet-rich fibrin matrix (PRFM) and platelet-rich fibrin gel (PRFG) preparation system for surgical applications. Uses a closed system to concentrate platelets and growth factors without thrombin, providing scaffold, signals, and cells for bone grafting procedures. Used by surgeons and surgical centers.
• Fibrinet PRF Wound Matrix FDA-cleared point-of-care system that creates a platelet-rich fibrin matrix (PRFM) from the patient's own blood to support natural wound healing without exogenous activators like thrombin. Available in Single Kit (up to 6 cm²) and Double Kit (up to 12 cm²). Used by wound care specialists and podiatrists managing chronic wounds including diabetic ulcers.
• Maxx-Cell Bone marrow aspiration device that harvests high-quality stem and progenitor cells from multiple levels within the marrow space while limiting peripheral blood contamination. Point-of-care device requiring no centrifugation. Designed for orthopedic surgeons and pain management specialists.
• MAXX BMC Bone marrow concentration system using patented Lead Screw Technology to concentrate bone marrow aspirate with elevated stem cell concentration. Processes 25-240cc of autologous bone marrow in 8 minutes with customizable platelet and hematocrit options. For orthopedic surgeons.
• MAXX PRP Platelet-rich plasma system providing 4-6x platelet concentration over baseline. Features dual spin capability, closed sterile system, 8-minute processing time, and Lead Screw Technology for precise buffy coat collection. For orthopedic and wound care specialists.
• Osteo-Spin Patented point-of-care live cellular graft technology platform that creates a customizable auto/allograft blend by centrifuging activated platelets and bone marrow aspirate at 3600 RPM without toxic cryoprotectants. For orthopedic surgeons and bone grafting procedures.
• Advanced Cell Advanced bone grafting and fusion convenience kit combining three technologies in one package: Maxx-Cell for bone marrow aspiration, Bio-Reign 3D synthetic scaffold, and an autograft harvesting system. For orthopedic surgeons performing bone grafting and fusion procedures.
• Magnus DMSO-free cryoprotectant cellular bone allograft providing osteoconductive scaffold with cortical and cancellous components. Features optimized 100-300μm particle size and minimum 150,000 cells per cc. For orthopedic surgeons performing spinal fusion and bone grafting.
• Maxx Fuse Complete range of demineralized bone matrix (DBM) products made from 100% human bone. Available in putty, sponge, and chips forms. Osteoconductive and osteoinductive with handling characteristics suited for surgical use. For orthopedic surgeons.
• Bio-Reign 3D Next-generation non-mineralized synthetic bone void filler using hyper-crosslinked carbohydrate polymer technology. Features 75-95% porosity with macropores (100-500μm) and micropores (<100μm), radiolucent upon implantation, and a degradation profile that matches bone formation. For orthopedic surgeons.
• Bio-Reign Bioactive bone graft matrix combining carbonate apatite anorganic bovine bone mineral, 45S5 bioactive glass, and Type I collagen. Provides osteoconductive scaffold for bone regeneration with natural mineral structure similar to human bone. For orthopedic surgeons.
• Bio-Reign Luxe Innovative bioactive, bioresorbable synthetic bone graft putty composed of 80% hydroxyapatite and 20% beta-tricalcium phosphate with 75-80% overall porosity. Features three pore sizes for optimal osteointegration. Available in 1.0cc, 3.0cc, 5.0cc, and 10.0cc syringe configurations. For orthopedic surgeons.
• Cold Plasma Therapy Wound care cold plasma therapy product offered through strategic partnership with Coldplasmatech GmbH. Distributed by Royal Biologics as part of its Royal Wound-X wound care portfolio. For wound care specialists.
• Collagen Type Zero Jellyfish-derived Type Zero collagen regenerative biomaterial brought to U.S. market through strategic partnership with UK-based Jellagen Ltd. Royal Biologics holds exclusive North American rights and will co-develop wound matrices and implantable regenerative solutions. For wound care and orthopedic surgeons.
• Myriad Matrix Restore Wound care product from Aroa Biosurgery distributed exclusively in the U.S. by Royal Biologics under an exclusive distribution agreement. For wound care specialists managing chronic and surgical wounds.

Quantifiable outcome

• 92% of wounds achieved ≥50% reduction in wound size with Fibrinet PRF Wound Matrix
• +3 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Four partnerships are on record, tiered flagship, core and minor.

• Jellagen Ltd (UK)flagshipStrategic or Co-development Partner · 24 February 2026Royal Biologics announced strategic partnership and investment with UK-based Jellagen Ltd to commercialize Collagen Type Zero, a jellyfish-derived regenerative biomaterial, in North American markets. Royal Biologics gains exclusive North American rights and will co-develop wound matrices and implantable regenerative solutions. CEO Salvatore Leo joins Jellagen's board as strategic commercialization lead. This partnership positions Royal Biologics as the first U.S. company to introduce jellyfish-derived collagen, creating a category-defining product line.
• Aroa BiosurgerycoreChannel Partner/ Reseller/ Distributor · 15 January 2026Royal Biologics entered into exclusive U.S. distribution agreement with Aroa Biosurgery for Myriad Matrix Restore product, expanding the company's wound care portfolio.
• Coldplasmatech GmbHcoreStrategic or Co-development Partner · 25 February 2025Strategic partnership with Coldplasmatech GmbH for cold plasma therapy wound care solutions. The company offers Cold Plasma Therapy as part of its wound care portfolio.
• VilexminorChannel Partner/ Reseller/ Distributor · 17 August 2021Royal Biologics announced partnership with Vilex launching its ALC (Amnion-Layer-Chorion) technology into the lower extremity industry, expanding wound care offerings.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Integra LifeSciences: Integra LifeSciences is a direct peer operating across wound care (skin substitutes, regenerative wound matrices) and orthobiologics, overlapping with Royal's Fibrinet PRF Wound Matrix and Bio-Reign bone graft lines. Both target hospitals and surgeons with FDA-cleared biologic implants.
• Organogenesis: Organogenesis is a focused wound care biologics company (Apligraf, Dermagraft, PuraPly) competing directly with Royal Wound-X's skin substitute and wound matrix offerings in diabetic foot ulcer and chronic wound markets.
• MiMedx: MiMedx develops placental-based allografts and wound care biologics (EpiFix, AmnioFix) directly competing with Royal's Fibrinet PRF Wound Matrix and distributed regenerative wound products in the chronic wound care channel.
• Bioventus: Bioventus is an orthobiologics pure-play with bone graft substitutes, PRP systems, and cellular allografts overlapping directly with Royal's Maxx-Cell, MAXX PRP, and Bio-Reign product lines targeted at orthopedic surgeons.
• MTF Biologics: MTF Biologics is a tissue bank and orthobiologics developer with allograft bone grafts and wound care matrices comparable to Royal's Magnus cellular bone allograft and Maxx Fuse DBM product family.
• Aroa Biosurgery: Aroa Biosurgery develops soft-tissue regeneration products (Myriad Matrix) and is simultaneously a Royal Biologics partner via exclusive U.S. distribution, making it a directly comparable wound care biologics peer.

Broad incumbents

• Stryker: Stryker is a broad medical device incumbent whose orthobiologics and regenerative medicine portfolio (including Wright Medical assets) competes with Royal across bone grafts, PRP, and cellular bone allografts in spine and extremities.
• Medtronic: Medtronic's Spine division sells orthobiologic bone grafts and cellular allografts (Infuse, MagniFuse) overlapping with Royal's Magnus and Bio-Reign portfolio in spinal fusion applications.
• Zimmer Biomet: Zimmer Biomet offers bone graft substitutes, regenerative technologies (RBx, OsteoAMP), and biologics portfolio competing broadly with Royal's orthobiologics offerings in joint reconstruction and trauma.
• Globus Medical: Globus Medical has built a musculoskeletal biologics franchise (including NuCel spine allograft) overlapping with Royal's Magnus cellular bone allograft targeted at MIS-TLIF and spinal fusion procedures.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/royalbiologics
• Facebookfacebook.com/RoyalBiologicsinc
• LinkedInlinkedin.com/company/royal-biologics-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Royal Biologics